Design and synthesis of selective and potent orally active S1P5 agonists.
Mattes
Henri
H
Novartis Institute for Biomedical Research, Basel Switzerland. henri.mattes@novartis.com
Dev
Kumlesh Kumar
KK
Bouhelal
Rochdi
R
Barske
Carmen
C
Gasparini
Fabrizio
F
Guerini
Danilo
D
Mir
Anis Khusro
AK
Orain
David
D
Osinde
Maribel
M
Picard
Anne
A
Dubois
Celine
C
Tasdelen
Engin
E
Haessig
Samuel
S
D000284:Administration, Oral; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D003198:Computer Simulation; D015195:Drug Design; D000068876:Fingolimod Hydrochloride; D008969:Molecular Sequence Data; D004676:Myelin Basic Protein / Q000378:metabolism; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism; D010793:Phthalazines / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D011409:Propylene Glycols / Q000737:chemistry; D051381:Rats; D049349:Receptors, Lysosphingolipid / Q000819:agonists* / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives / Q000737:chemistry; D013329:Structure-Activity Relationship
D004676:Myelin Basic Protein; D010793:Phthalazines; D011409:Propylene Glycols; D049349:Receptors, Lysosphingolipid; C043388:phthalazine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine